Drugs / T-Guard
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04934670 | Jun → Nov 2022 | acute graft versus host disease | Xenikos | Terminated | No outcome recorded |
| Phase 3 | NCT04128319 | Nov 2019 → Feb 2020 | acute graft versus host disease | Xenikos | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-Guard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04934670 ↗ |
| Action | Deplete | “leading to depletion of allo-reactive T cells” NCT04128319 ↗ |
| Modality | Protein / enzyme biologic | “Combination Anti-CD3/CD7 Immunotoxin (T-Guard)” NCT04128319 ↗ |
| Route | Intravenous | “administered intravenously” NCT04128319 ↗ |
| Target | CD7 | “Anti-CD3/CD7 immunoconjugate” PMID 37749187 ↗ Sep 2023 |